Pattern Bioscience, an innovator in rapid infection #diagnostics, just secured a $22.5M Biomedical Advanced Research and Development Authority (BARDA) contract to advance their single-cell #microbiology system. This technology enables same-day identification of pathogens and their antibiotic susceptibility—cutting diagnostic time from days to hours.? ?? We’re proud to support Pattern as they improve infection care and drive better patient outcomes.? ? Learn more in the full press release: https://lnkd.in/gWv8u5hn? ? #PartnerNews #SingleCell??
关于我们
Illumina Ventures is an independently managed firm focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. We invest in life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health. Our strategic relationship with Illumina provides us access to the expertise and vision of the world's leading genomics solutions provider. Our team members have decades of entrepreneurial experience in genomics and a passion for improving human health.
- 网站
-
https://www.illuminaventures.com
Illumina Ventures的外部链接
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 2-10 人
- 总部
- San Francisco，CA
- 类型
- 合营企业
- 创立
- 2016
- 领域
- Venture Capital、Genomics、Life Sciences、Private Equity、Precision Medicine和Start Ups
地点
-
获取路线
499 Illinois Street, Suite 210
US，CA，San Francisco，94158-2509
Illumina Ventures员工
动态
-
DELFI Diagnostics has partnered with Lahey Hospital & Medical Center to bring the FirstLook Test to the greater Boston area.? ?? With screening rates under 10% nationwide, this simple, blood-based test offers a more accessible way to detect #LungCancer early, potentially saving lives. FirstLook? Lung uses advanced #MachineLearning to analyze cfDNA fragments, identifying #cancer with a 99.8% negative predictive value.? ?? By combining DELFI’s #innovation with Lahey’s leadership in lung cancer screening, this collaboration aims to transform early detection and outcomes.? ?? ?? Learn more: https://lnkd.in/gYHDdBBb? ?? #PartnerNews #CancerDetection #diagnostics??
-
-
Congratulations to Tagomics on their strategic co-marketing agreement with Agilent Technologies. This partnership combines Tagomics’ Interlace? #multiomics platform with Agilent's SureSelect technologies, delivering a seamless workflow for comprehensive genomic and epigenetic profiling.? ?? Through an exclusive technology access program, select customers will gain insights into the mechanisms driving disease, paving the way for groundbreaking diagnostic and therapeutic advancements.? ?? We’re proud to support Tagomics as they push the boundaries of biomarker #discovery and #innovation.? ? Read more: https://lnkd.in/eMTt6pt7? ? #genomics #epigenetics #oncology #diagnostics #therapeutics?
-
-
On November 19 at 2:30 pm ET, virtually join Illumina Ventures Partner Mara Aspinall, DELFI Diagnostics CEO Susan Tousi, and LetsGetChecked Chief Genomics Officer Avni Santani as they discuss transformative approaches in #cancer management, including:? ?? ?? Models for equitable, accessible cancer testing? ?? The impact of genetic testing on hereditary cancers? ?? Programs identifying individuals at risk for lung cancer? ?? Strategies for employers and health plans to manage costs and enhance outcomes? ?? Register for the webinar here: https://lnkd.in/gPGxxPdn?
-
-
Arnaud Autret, Illumina Ventures Head of European Operations, will be at the EIC and Johnson & Johnson Healthcare Investor Day in Paris on Wednesday, November 13. ? ? This event, organized by EuroQuity - Bpifrance, will gather some of the most qualified European investors looking for groundbreaking solutions in the sector. EIC beneficiaries will pitch their innovations, with the added benefit of receiving exclusive training and the possibility of being invited to one-to-one meetings and follow-up.? ? Please reach out to Arnaud for connection opportunities. https://lnkd.in/gb-Pru6M?
-
-
?? Mark your calendars for Thursday, November 14th for SuperGLUE 2024!? ? Global Lectures Uniting Everyone (GLUE) is the Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) flagship event fostering collaborations and innovations for point-of-care diagnostics. ? ??? Mara Aspinall, Illumina Ventures Partner, will give the keynote address “Transforming Healthcare: The Power and Potential of Point-of-Care Diagnostics.” ? ?? Learn more: https://lnkd.in/ex6jMAnk? ?? #Diagnostics #HealthcareInnovation #PointofCareDiagnostics #ACME #POCT?
-
-
Congrats to the Iambic team on the preview launch of NeuralPLexer3 Beta! This next-gen #AI model redefines #DrugDiscovery with rapid, high-precision protein-ligand predictions. Researchers now have a valuable tool to accelerate therapeutic exploration across diverse protein classes, moving past traditional roadblocks in structure-based design.? ?? #PartnerNews?
Today we are previewing our next-generation NeuralPLexer3 Beta AI model, which sets new standards for protein-ligand structure prediction – transforming structure determination from a bottleneck into a truly interactive tool for drug discovery. NeuralPLexer3 Beta enables researchers to explore therapeutic hypotheses with unprecedented accuracy and speed. Trained on datasets encompassing a vast array of biologic structures and interaction types, the new model provides researchers instant, accurate structural insights across the full range of protein classes and drug molecules. This next version of NeuralPLexer is a significant step toward fully AI-enabled structure-based drug design. Learn more here:?https://lnkd.in/gyiGdKZy #AI #BioTech #Healthcare #Innovation #NeuralPLexer
-
Congrats to Iambic Therapeutics, a cutting-edge #biotechnology research company shaping the future of #AI in medicine, for their launch of Enchant! This multimodal AI model strengthens Iambic’s ability to refine the selection of clinical drug candidates, potentially helping safer and more effective #treatments reach patients faster. Learn more: https://lnkd.in/gdd5zsRy #PartnerNews
-
-
What’s the potential impact of DELFI Diagnostics' cancer detection tests on healthcare? DELFI’s dynamic CEO Susan Tousi answers that question in this month’s Illumina Ventures CEO Spotlight. Susan discusses the unique population that can benefit from DELFI’s cancer detection test, the opportunities that lie ahead, and why the investment from Illumina Ventures is so important. Visit the website to hear more from our conversation: https://lnkd.in/eFcb4yCP
-
Congratulations to DELFI Diagnostics on their collaboration with Florida Lung Health Coalition, RadNet, and the American Lung Association to launch a new lung cancer screening and detection initiative in Florida. This November for #LungCancer Awareness Month, eligible patients can access the FirstLook Lung test—a simple blood test to identify at-risk individuals. Elevated results will prompt a low-dose CT scan, boosting early detection rates in Florida, where only 15.8% are currently screened. Learn more: https://lnkd.in/gKMhEzGW #PartnerNews
-